VERA
Income statement / Annual
Last year (2025), Vera Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Vera Therapeutics Inc's net income was -$299.62 M.
See Vera Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$468.00 K
|
$0.00
|
$0.00
|
-$846.00 K
|
$0.00
|
$251.00 K
|
$509.00 K
|
| Gross Profit |
-$468.00 K
|
$0.00
|
$0.00
|
$846.00 K
|
$0.00
|
-$251.00 K
|
-$509.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$215.26 M
|
$126.17 M
|
$78.23 M
|
$69.84 M
|
$22.48 M
|
$43.92 M
|
$7.29 M
|
| General & Administrative Expenses |
$100.22 M
|
$41.00 M
|
$23.79 M
|
$0.00
|
$11.92 M
|
$0.00
|
$4.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$100.22 M
|
$41.00 M
|
$23.79 M
|
$21.91 M
|
$11.92 M
|
$3.89 M
|
$4.41 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$315.47 M
|
$167.17 M
|
$102.01 M
|
$91.75 M
|
$34.40 M
|
$47.81 M
|
$11.70 M
|
| Cost And Expenses |
$315.47 M
|
$167.17 M
|
$102.01 M
|
$90.90 M
|
$34.40 M
|
$48.06 M
|
$11.70 M
|
| Interest Income |
$24.48 M
|
$20.71 M
|
$7.98 M
|
$1.75 M
|
$15.00 K
|
$8.00 K
|
$159.00 K
|
| Interest Expense |
$7.53 M
|
$7.63 M
|
$3.79 M
|
$992.00 K
|
$20.00 K
|
$166.00 K
|
$51.00 K
|
| Depreciation & Amortization |
$468.00 K
|
$105.00 K
|
$21.00 K
|
-$846.00 K
|
$176.00 K
|
$251.00 K
|
$509.00 K
|
| EBITDA |
-$291.62 M |
-$144.42 M |
-$92.18 M |
-$88.91 M |
-$32.41 M |
-$53.00 M |
-$11.29 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$15.86 M
|
$15.02 M
|
$6.02 M
|
$1.85 M
|
$1.79 M
|
-$5.35 M
|
$108.00 K
|
| Income Before Tax |
-$299.62 M
|
-$152.15 M
|
-$95.99 M
|
-$89.06 M
|
-$32.61 M
|
-$53.41 M
|
-$11.85 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
| Net Income |
-$299.62 M
|
-$152.15 M
|
-$95.99 M
|
-$89.06 M
|
-$32.61 M
|
-$53.41 M
|
-$11.85 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.66 |
-2.75 |
-2.25 |
-3.35 |
-2.43 |
-14.4 |
-3.46 |
| EPS Diluted |
-4.66 |
-2.75 |
-2.25 |
-3.35 |
-2.43 |
-14.4 |
-3.46 |
| Weighted Average Shares Out |
$64.23 M
|
$55.33 M
|
$42.71 M
|
$26.57 M
|
$13.44 M
|
$3.71 M
|
$3.42 M
|
| Weighted Average Shares Out Diluted |
$64.23 M
|
$55.33 M
|
$42.71 M
|
$26.57 M
|
$13.44 M
|
$3.71 M
|
$3.42 M
|
| Link |
|
|
|
|
|
|
|
